A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.
Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.
Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City. “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."
For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.
Dining, Managed Risk
Every experience your residents have inside your restaurant can determine the success of your community. From the stickiness of your tables to whether...
Elder Abuse, Managed Risk
The National Institutes of Health has launched a public health campaign on the link between hypertension and cognitive decline and dementia.
Health and Wellness, Managed Risk
Be sure to wash your hands on Sunday before any high-fives at a Super Bowl party, says a Cornell University economist who found that geographical area...
Facts and Figures, Memory Care Best Practices and Research, Memory Care Education, Reports
Eating more seafood is not linked to a likelihood of developing Alzheimer’s disease and in fact may help in preventing cognitive decline, according to...
Business, CEO, cheatsheet, Clinical Quality and Quality Care Delivery, Community Awareness and Education, Engage, Membership
Argentum has announced a key first step in defining a model for quality and accountability in senior living by introducing a first generation of quali...
Tools for prolonging and improving cognitive ability help many senior living residents stay sharp.
Geriatrician and memory care expert Dr. G. Allen Power on how senior living can support a much-needed focus on well-being and engagement.
Health Care, Managed Risk, Medication Technology & Informatics
The Food and Drug Administration has issued draft guidance for managing cybersecurity vulnerabilities for marketed medical devices, encouraging manufa...
Federal Agency Activity, Health Care, Managed Risk
The U.S. Health and Human Services Department has issued new guidelines designed to make it easier for patients to access their medical records.
End of Life, Facts and Figures, Health and Wellness, Managed Risk, Medication Management, Reports
Senior living communities could reduce emergency department visits by implementing telemedicine, according to a new study published in Telemedicine an...